Curis rises on Genentech US NDA submission for skin cancer drug
This article was originally published in Scrip
Executive Summary
Shares of Curis gained as much as 8.6%, or 25 cents, on 12 September after its partner Genentech reported that it submitted a new drug application (NDA) to the US FDA for vismodegib as a treatment for patients with advanced, inoperable basal cell carcinoma (BCC).